West Chester, PA, United States of America

Karla K Kopec

This inventor holds 1 USPTO granted patent and 4 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: 89Bio, Inc.. Active years: 2019.

USPTO Granted Patents = 1 

% Patents Active = 100.0


 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Karla K Kopec: Innovator in Biopharmaceuticals

Introduction

Karla K Kopec is a notable inventor based in West Chester, PA (US). She has made significant contributions to the field of biopharmaceuticals, particularly through her innovative work on peptide conjugates.

Latest Patents

Karla holds a patent for "Mutant FGF-21 peptide pegylated conjugates and uses thereof." This invention relates to a mutant Fibroblast Growth Factor-21 (FGF-21) peptide conjugate that comprises a PEG moiety attached to a mutant FGF-21 peptide via a glycosyl linker. The patent also details a method for producing this mutant FGF-21 peptide conjugate, along with a pharmaceutical composition and container that includes the conjugate.

Career Highlights

Karla is currently associated with 89Bio, Inc., where she continues to advance her research and development efforts in the biopharmaceutical sector. Her work is pivotal in exploring new therapeutic avenues for various medical conditions.

Collaborations

Karla collaborates with Patrick Mengyuan Liu, contributing to the innovative environment at 89Bio, Inc. Their partnership exemplifies the collaborative spirit essential for breakthroughs in the biopharmaceutical industry.

Conclusion

Karla K Kopec's contributions to the field of biopharmaceuticals through her patent on mutant FGF-21 peptide conjugates highlight her role as an influential inventor. Her ongoing work promises to impact the development of new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…